Further in vitro and in vivo studies will clarify the impact of hepcidin inhibition during M. tuberculosis infection, but the recent studies with other siderophilic bacteria strongly support the hepcidin-ferroportin axis as promising novel HDT for TB. The gene discussed is HAMP; the disease is tuberculosis.